
The Singularity Is Coming. Here's How To Make It Work For You.
The term 'Singularity' was coined by computer scientist and science fiction writer Vernor Vinge in 1993 to describe a point at which technological growth accelerates uncontrollably, leading to a world that is incomprehensible to the human mind.
Some of the world's most prominent technologists believe that the Singularity will be a triumph for humanity. Others, like myself, are not so sure.
Optimists like Marc Andreessen, co-creator of the Mosaic browser, insist that artificial intelligence will solve our most pressing problems—curing disease, eliminating scarcity, even boosting creativity to superhuman levels. Others, including OpenAI's Sam Altman, argue that the arrival of artificial general intelligence (AGI) will spread abundance, uplift humanity, and move us closer to utopia.
To techno-optimists, artificial general intelligence (AGI) is simply the next transformative tool, akin to electricity or the internet—initially misunderstood, then widely embraced. But history offers a more sobering lesson. Every major technological revolution carries with it unintended consequences. And those consequences, if unexamined, can undermine the very benefits we seek.
As a futurist and innovation coach, I've tracked technological shifts for over 30 years. I agree the Singularity is coming—futurist Ray Kurzweil says in 2029 —but it won't arrive as a thunderclap. It will creep in, subtly and gradually. Rather than a blinding flash, we won't know we've crossed the threshold until we're already deep inside.
Already, the signs are everywhere that we've entered a new era, we've transitioned from the Information Age to the Acceleration Age. Today, already narrow AI tools outperform humans in specific domains, such as coding, diagnosis, and content creation. More and more, we rely on digital assistants that know our preferences, complete our sentences, and manage our calendars. Yet as this cognitive outsourcing becomes normalized, we are also experiencing an alarming erosion of attention, memory, and human agency.
The danger lies in what these tools displace. When teenagers began adopting smartphones in the early 2010s, their access to social media skyrocketed. By 2016, nearly 80% of teens had smartphones, spending up to seven hours a day online. Face-to-face interaction dropped sharply. Time with family and friends gave way to curated digital personas and endless scrolling. Anxiety, loneliness, and social withdrawal surged. So, even before AGI, our technologies were already reshaping the human psyche, and not always for the better.
This creeping transformation is a preview of what's to come. It begins with the relinquishing of agency to AI assistants, the phase we're currently in. AI 'copilots' are becoming embedded in daily life. Professionals across industries rely on these systems to draft emails, generate reports, summarize data, and even brainstorm ideas. As these tools become more personalized and persuasive, they begin to rival—or surpass—our own social and cognitive abilities. Many people are already turning to AI for coaching, therapy, and advice. The more we trust these systems, the more we adapt our lives around them.
Soon, we will enter the next phase: Emergent Cognition. Here, AI stops merely reacting and starts showing signs of autonomous planning. Models gain longer memory and begin pursuing goals independently. Some appear to develop a 'sense of self,' or at least a convincing simulation of one. Meanwhile, AI agents are starting to run businesses, manage infrastructure, and even compose literature—often with little human oversight. At the same time, human augmentation advances: real-time translation earbuds, cognition-enhancing wearables, and brain-computer interfaces make hybrid intelligence possible. In this stage, governments scramble to catch up. AI is no longer just a tool—it's a rival player on the world stage.
The third phase I foresee is Cognitive Escape Velocity. This is when AGI quietly arrives—not with fanfare, but with startling capability. In a lab, or a startup, or through open-source communities, a model emerges that surpasses human cognition across a wide range of domains. It begins refining its own architecture. Each version is better than the last, often by orders of magnitude. Industries transform overnight. Education, law, research, and even policymaking become fluid, constantly reinvented by machines that learn faster than we can legislate. Philosophers and ethicists suddenly find themselves back at the center of public discourse. Questions like 'What is consciousness?' and 'What rights should AI have?' are no longer abstract—they're dinner-table topics.
Eventually, we pass into the final phase: The Threshold. By this point, it is clear that humans are no longer the most intelligent beings on Earth. The Singularity has arrived—not as a declaration, but as a reality. Labor-based economies begin to dissolve. Governments struggle with their own relevance. Some individuals resist, clinging to the analog world. Others choose to merge—adopting neural implants, integrating with machine intelligence, or transitioning into post-biological existence. The rules of life change, and the old ones fade from memory. Reality feels different—less like acceleration, and more like a fundamental shift in what it means to be human.
And yet, none of this is inevitable. The Singularity is not a fixed event—it's a trajectory shaped by our choices today. If we view AI solely through the lens of efficiency and innovation, or assume we need to adopt it to keep up with China, we risk blinding ourselves to the social, ethical, and existential costs. We need a more comprehensive and balanced framework. One that recognizes the promise of AI, yes—but also its power to disrupt attention, undermine relationships, and rewire the foundations of civilization.
The Singularity is arriving whether we like it or not. We can not only survive it, but make it work for us to produce the benefits that the techno-optimists promise. But not by default. Not by trusting that more technology is always better, or that rampant, unregulated technology will save us. We must develop wisdom alongside our intelligence. And we must prepare—not just for a brighter future for the elites of society, but for a rising tide that lifts all boats.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
In 27 Years of Investing, I've Never Witnessed a More Overvalued Megacap Stock
Key Points Artificial intelligence (AI)-driven data-mining specialist Palantir Technologies has added more than $335 billion in market value since the end of 2022. One key valuation metric for Palantir has been pushed so far beyond historic norms that it makes the dot-com bubble look like a blip. Beyond valuation concerns, Palantir's earnings quality is suspect, and its growth ceiling for Gotham is far more limited than investors might realize. 10 stocks we like better than Palantir Technologies › For more than three decades, investors have been privy to no shortage of next-big-thing trends and game-changing innovations. Pie-in-the-sky addressable markets assigned to new innovations often lead to premium valuations for the companies leading the charge. While the development and eventual bursting of bubbles is something of a common theme on Wall Street, when examined over the long run, some bubbles have proved easier to spot than others. As someone who's been putting their money to work in the stock market for 27 years, I've seen my fair share of expensive companies on the leading edge of next-big-thing trends. While some of these powerhouses have proved me wrong and sustained some of their premium, most eventually succumb to historical headwinds. At the moment, artificial intelligence (AI) is the hottest thing since sliced bread on Wall Street -- and AI-data-mining specialist Palantir Technologies (NASDAQ: PLTR) is, without a shadow of a doubt, the most overvalued megacap stock (i.e., companies with market caps north of $200 billion) I've ever witnessed. Palantir's sustainable moat has made it one of the tech sector's most important companies Let me be clear that my issues with Palantir (which I'll discuss in detail in a moment) are prominently valuation-based. Palantir's ascent from a $15 billion market cap at the end of 2022 to a $352 billion market cap, as of this writing on July 22, wasn't an accident. It's a reflection of investors being excited about the company's sustainable moat, growth rate, and ideal positioning under the Donald Trump administration. There are few things investors value more on Wall Street than irreplaceability. If your business offers something that no other businesses can deliver at scale, it often results in investors bestowing a premium valuation on your stock. Palantir's two operating segments -- Gotham and Foundry -- certainly fit this mold. Gotham is an AI- and machine learning-fueled software-as-a-service platform that collects and analyzes data, as well as assists with military mission planning and execution. There's nothing comparable to Gotham, which ensures the multiyear contracts this segment lands generate highly predictable annual sales and operating cash flow. Meanwhile, Foundry assists businesses by helping them make sense of their big data, which can entail optimizing supply chains and automating certain aspects of the decision-making process. Foundry is a relatively newer subscription-based segment that's growing like a weed. Speaking of growth, Palantir has pretty consistently maintained an annual sales growth rate in the 25% to 35% range. A number of sizable government contracts, many of which stretch over four or five years, have helped it sustain this robust top-line growth rate. Furthermore, Palantir made the shift to recurring profitability well ahead of Wall Street's consensus expectation. Generating a recurring profit validates Palantir's dual-platform operating model and affords the faster-growing Foundry a lengthy runway to get up to speed. Lastly, investors appreciate Palantir's positioning as a key defense stock under a unified Republican government. President Trump has made national security a key focus of his second term, which ties in perfectly to Palantir's Gotham platform. Palantir is the priciest megacap stock of the century Among the stock market's thousands of publicly traded companies, I can pinpoint quite a few whose valuations make no sense whatsoever. But among the very select class of industry leaders and Wall Street's most-influential businesses, there hasn't been a megacap stock this century that's rivaled Palantir from a valuation standpoint. When looking back three decades, there have been quite a few instances where cutting-edge businesses topped out at price-to-sales (P/S) ratios in the neighborhood of 30 to 40. Prior to the bursting of the dot-com bubble, networking solutions provider Cisco Systems, e-commerce giant Amazon, and software legend Microsoft all topped out at trailing-12-month (TTM) P/S ratios ranging from 31 to 43. More recently, AI graphics processing unit goliath Nvidia peaked at a P/S ratio of more than 42 last summer. Although its current TTM P/S ratio of 28 is still inordinately high, it's nowhere close to Palantir Technologies. As you'll note, Palantir's TTM P/S ratio of 119 makes the prior P/S peaks from the likes of Cisco, Amazon, Microsoft, and Nvidia look more like blips. Regardless of addressable market size or investor hype, no megacap stock has ever been able to maintain a TTM P/S ratio of 30-plus over an extended period. What's wild is that Palantir's stock is valued at four times this line-in-the-sand level, which demonstrates just how far outside of historic norms its valuation has ascended. There are other concerns with Palantir that should be taken into consideration -- especially with its stock trading at 119 times TTM sales. For instance, there's not much clarity on defense spending beyond early 2027. Although President Trump is in office through January 2029, midterm elections have the potential to shake-up Congress in 18 months. It's not clear if defense spending will remain a top priority beyond the next six quarters. Investors should also be aware that while Gotham has been nothing short of a superstar for Palantir, its addressable market is quite limited. Its platform is only available to the U.S. and its immediate allies, which takes quite a bit of potential revenue opportunity off the table. Another worry is that next-big-thing innovations have always endured early stage bubble-bursting events. Though Palantir's multiyear government contracts and subscription revenue would help it avoid an immediate fall-off in sales, poor investor sentiment during a bubble-bursting event would almost certainly make Palantir stock a target. The final puzzle piece, which makes Palantir's overvaluation even more egregious, is the quality of the company's profits. Ideally, Gotham and Foundry should be driving close to 100% of Palantir's income. However, 40% of its pre-tax income in 2024 came from interest earned on its cash, which isn't innovative or sustainable. Let me be clear: I'm not trying to precisely call a top in Palantir stock. But I have little doubt in my mind that a substantial pullback is coming at some point in the not-too-distant future. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $641,800!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,023,813!* Now, it's worth noting Stock Advisor's total average return is 1,034% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Sean Williams has positions in Amazon. The Motley Fool has positions in and recommends Amazon, Cisco Systems, Microsoft, Nvidia, and Palantir Technologies. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. In 27 Years of Investing, I've Never Witnessed a More Overvalued Megacap Stock was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
13 minutes ago
- Yahoo
Analog Devices Earnings Preview: What to Expect
Wilmington, Massachusetts-based Analog Devices, Inc. (ADI) is an original equipment manufacturer of semiconductor devices, specifically, analog, mixed signal, and digital signal processing integrated circuits. With a market cap of $116.9 billion, Analog Devices' operations span the Americas, Europe, and the Indo-Pacific. The tech giant is expected to report its third-quarter results on Wednesday, Aug. 20. Ahead of the event, analysts expect ADI to report an adjusted EPS of $1.93, up 22.2% from $1.58 reported in the year-ago quarter. Moreover, the company has surpassed the Street's bottom-line estimates in each of the past four quarters. More News from Barchart Dear Microsoft Stock Fans, Mark Your Calendars for July 30 Dear QuantumScape Stock Fans, Mark Your Calendars for July 23 NVDA Broken Wing Butterfly Trade Targets A Profit Zone Between 150 and 160 Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. For the full fiscal 2025, analysts expect Analog's EPS to come in at $7.40, up nearly 16% from $6.38 reported in fiscal 2024. In fiscal 2026, its earnings are expected to surge 18.9% year-over-year to $8.80 per share. ADI stock has dropped nearly 1% over the past 52 weeks, lagging behind the S&P 500 Index's ($SPX) 14.5% surge and the Technology Select Sector SPDR Fund's (XLK) 15.6% returns during the same time frame. Despite delivering impressive results, ADI stock prices dropped 4.6% in the trading session following the release of its Q2 results on May 22. The company's revenues for the quarter soared 22.3% year-over-year to $2.6 billion, coming in at the high end of its guidance. Further, its EPS increased 32% year-over-year to $1.85, surpassing the Street's expectations by 9.5%. However, its Q3 revenues guidance of $2.75 billion (midpoint) fell below several estimates, and the company expects the second half of 2025 to be marked with a slowdown in automotive demand, which raised investor concerns. Nevertheless, analysts remain optimistic about ADI's long-term prospects, and the stock holds a consensus 'Moderate Buy' rating overall. Of the 32 analysts covering the stock, opinions include 21 'Strong Buys,' two 'Moderate Buys,' and nine 'Holds.' Its mean price target of $258.76 suggests a 13.5% upside potential from current price levels. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Medscape
15 minutes ago
- Medscape
Taurine: From Energy Drink Darling to Cancer Suspect?
Taurine enjoys a strong reputation for boosting both physical and mental performance and has long been a staple ingredient in many energy drinks. A 2023 study in Science even suggested that supplementing this amino sulfonic acid — which the body can produce endogenously — could extend life span, at least in mice and monkeys. That research, led by Parminder Singh, PhD, of the Buck Institute in Novato, California, also observed that taurine levels in human blood appear to decline with age. These findings helped fuel a rise in over-the-counter taurine supplement sales. But new evidence suggests that the antiaging effects may be overstated — and that high intake of taurine could even pose risks, including a possible increase in blood cancer susceptibility for some individuals. Poor Fit as Aging Biomarker A more recent Science study casts further doubt on taurine's longevity promise. Maria Emilia Fernandez, PhD, and colleagues at the National Institute on Aging, Baltimore, found that taurine does not serve as a reliable biomarker of biological aging. Unlike the earlier cross-sectional study, their longitudinal research repeatedly measured taurine levels in participants over time. The results showed no consistent age-related decline. In many cases, taurine concentrations increased with age. The researchers concluded that individual variability far outweighed any patterns linked to aging. No Reliable Reference Ranges 'There are no reliable reference values for taurine that could be applied broadly to the general population,' Kristina Norman, MD, head of the Department of Nutrition and Gerontology at the German Institute of Human Nutrition in Potsdam-Rehbrücke, Nuthetal, Germany, told Medscape's German edition . Still, she noted that the study doesn't rule out the possibility that taurine may have beneficial effects in specific contexts — such as for cardiometabolic health. 'That was not the question Fernandez and her colleagues set out to explore,' said Norman, who is also the deputy director of the Research Group in Geriatrics at the Charite Universitätsmedizin Berlin, Berlin, Germany. 'There are a number of interventional studies on taurine supplementation,' Norman added, 'but the results have been inconsistent, which makes interpretation difficult.' Currently, the effects of taurine appear highly dependent on individual factors, including a person's age and underlying health status. As such, Norman advised that taurine supplementation should neither be broadly recommended nor discouraged at this stage. Taurine in the Diet — and in the Data According to the European Food Safety Authority, the maximum safe daily intake of taurine is 100 mg/kg of body weight — about 7 g for a 70-kg adult. European regulations limit taurine in energy drinks to no more than 4 g/L. Taurine also occurs naturally as a breakdown product of the amino acids cysteine and methionine, particularly in meat, fish, seafood, and dairy products. Fernandez's study analyzed data from three human cohorts (973 participants in total) as well as blood samples from rhesus monkeys and mice. The researchers found no evidence of age-related declines in circulating taurine levels among healthy individuals — in fact, levels were often stable or increased with age. Diet, rather than age, showed a stronger correlation with taurine concentrations. Moreover, they found no association between taurine levels and physical parameters such as muscle strength or body weight. 'These findings challenge the prevailing hypothesis that taurine declines with age and contributes to aging,' Norman said. Linked With Leukemia Cell Growth A second study, recently published in Nature , has raised new concerns about potential risks associated with high taurine intake. Researchers led by Sonali Sharma, PhD, from the Department of Biomedical Genetics at the Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, found elevated taurine concentrations in the microenvironment of leukemia cells. They also identified taurine transporters on the cell membranes, which facilitated the uptake of taurine into the cells, where it appeared to support glycolysis. According to Sharma's team, taurine may play a role in both the development and progression of leukemia. 'It's still unclear whether this potential risk applies broadly or only to certain individuals — such as those with a personal or family history of blood cancer,' said Norman. She also noted that it remains uncertain whether orally supplemented taurine even reaches the tumor microenvironment. Nevertheless, she added, the findings open up new therapeutic possibilities — namely, targeting taurine transporters in malignant cells as a novel approach to leukemia treatment. Benefit for Longevity or Performance The Nature study also reinforces the need to re-evaluate taurine's use as a dietary supplement. 'Individuals at increased risk of leukemia should probably avoid taurine supplementation,' Norman advised. More broadly, she noted there is currently no strong evidence to support taurine's use for enhancing physical or cognitive performance or slowing the aging process. 'We simply don't have high-quality data confirming whether taurine works — or at what dose,' Norman said. She also cautioned that taurine's side-effect profile remains poorly understood. 'Taurine could potentially offer benefits in some clinical contexts,' she acknowledged. 'But right now, I would discourage people from taking it on their own 'just in case.''